Boston Scientific Buys Rhythmia Medical; Sees Immaterial in FY13 and FY14
Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of next-generation mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology procedures, including atrial fibrillation and atrial flutter. Rhythmia Medical is based in Burlington, MA. The transaction is expected to close by Friday, October 12^th.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.